NeuroSense Therapeutics Ltd.
NRSN evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $9.1M
What it means
What to watch
Prepared research question
What matters most for NRSN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NRSN
NeuroSense Therapeutics Ltd. (NRSN) is a late-stage clinical biotechnology company developing PrimeC, a disease-modifying treatment for neurodegenerative diseases, with completed Phase 2b trials in ALS and Alzheimer's disease.
Key risk: Cash runway risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$9.1M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 2 clinical trials for NeuroSense Therapeutics Ltd..
NeuroSense Therapeutics Ltd. (NRSN) is a late-stage clinical biotechnology company developing PrimeC, a disease-modifying treatment for neurodegenerative diseases, with completed Phase 2b trials in ALS and Alzheimer's disease.
- NeuroSense's lead asset, PrimeC, achieved a statistically significant reduction in TDP-43 levels in the Phase 2b PARADIGM ALS study [news · published 2026-06-29].
- The company reported a 65% reduction in risk of death and greater than 14-month median survival benefit with PrimeC in ALS from long-term survival data [news · published 2026-02-18].
- FDA cleared NeuroSense to initiate a pivotal Phase 3 trial for PrimeC in ALS [news · published 2025-11-24].
- Positive biomarker findings were reported from the Phase 2 RoAD proof-of-concept study of PrimeC in Alzheimer's disease [news · published 2026-06-25].
- As of 2025-12-31, NeuroSense reported cash & equivalents of $0.2M and negative shareholders' equity of -$1.6M [sec].
What works
- PrimeC has demonstrated statistically significant clinical and biomarker results in a Phase 2b ALS trial, including a reduction in TDP-43 and a survival benefit [news · published 2026-06-29] [news · published 2026-02-18].
- The company has secured FDA clearance to initiate a pivotal Phase 3 trial for PrimeC in ALS, indicating regulatory alignment [news · published 2025-11-24].
- Positive biomarker data from the Phase 2 Alzheimer's study suggests potential expansion of PrimeC's utility beyond ALS [news · published 2026-06-25].
What to weigh
- Cash position is critically low at $0.2M as of 2025-12-31, with negative shareholders' equity of -$1.6M, indicating severe financial constraints [sec].
- The company is dependent on a single lead asset, PrimeC, for all major clinical programs, creating concentration risk [news · published 2026-03-24].
- Phase 3 trials in ALS and ongoing Alzheimer's studies require substantial capital, which may be challenging given the current cash runway [sec] [news · published 2026-08-31].
From the filings
Quoted directly from source documents.
PrimeC met primary endpoint in Phase 2b ALS study with TDP-43 reduction
“its Phase 2b PARADIGM study of PrimeC in amyotrophic lateral sclerosis (ALS) has successfully met its primary efficacy endpoint, demonstrating a statistically significant reduction in TDP-43 levels compared to placebo.”
News · June 29, 2026
65% reduction in risk of death and >14-month survival benefit in ALS
“Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS”
News · February 18, 2026
FDA clearance for Phase 3 ALS trial
“the U.S. Food and Drug Administration (FDA) has completed the review of the Investigational New Drug (IND) amendment application and authorized the Company to initiate the pivotal Phase 3 clinical trial for the evaluation of its lead drug candidate, PrimeC”
News · November 24, 2025
Catalyst timeline
- 2022-05-31 · Phase 2b ALS trial start (PARADIGM) — Initiation of the randomized, double-blind, placebo-controlled Phase 2b study of PrimeC in ALS.
- 2023-11-19 · Phase 2 Alzheimer's trial start (RoAD) — Initiation of the Phase 2 proof-of-concept study of PrimeC in mild to moderate Alzheimer's disease.
Risks & what to watch (3)›
Key risks
- Cash runway risk — Cash of $0.2M as of 2025-12-31 is extremely low for a late-stage biotech, threatening ability to fund Phase 3 and operations [sec].
- Single-asset dependency — All major programs rely on PrimeC; failure in Phase 3 ALS or Alzheimer's would be company-threatening [news · published 2026-03-24].
- Negative shareholders' equity — Shareholders' equity of -$1.6M as of 2025-12-31 indicates liabilities exceed assets, a sign of financial distress [sec].
What to watch
- Initiation and enrollment progress of the pivotal Phase 3 ALS trial for PrimeC [news · published 2025-11-24].
- Further biomarker or clinical readouts from the Phase 2 Alzheimer's RoAD study [news · published 2026-06-25].
- Any financing or partnership announcements to address the low cash position [sec].
- Regulatory interactions (e.g., FDA meetings) regarding PrimeC's accelerated approval pathway [news · published 2026-08-31].
Sources: Catalysts · News · Generated October 5, 2026 · How we verify sources →
Run NeuroSense Therapeutics Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NeuroSense Therapeutics Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
N/A
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$287K
| Holder | Shares | Value |
|---|---|---|
| yorkville advisors global, lp | 78,000 | $59K |
| independent advisor alliance | 50,000 | $38K |
| ubs group ag | 49,096 | $37K |
| two sigma investments, lp | 44,445 | $34K |
| meitav investment house ltd | 40,000 | $30K |
| jane street group, llc | 28,670 | $22K |
| commonwealth equity services, llc | 22,775 | $17K |
| pnc financial services group, inc. | 21,150 | $16K |
| pathstone holdings, llc | 16,528 | $12K |
| geode capital management, llc | 15,870 | $12K |
Showing top 10 of 13 institutional holders of NeuroSense Therapeutics Ltd.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 2.4%
- Days to cover
- 3.5
- Shares short
- 653,788
- Daily short volume (Aug 14, 2026)
- 45.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NRSN short interestFrequently asked questions
What is the AI investment thesis for NeuroSense Therapeutics Ltd.?
NeuroSense Therapeutics Ltd. (NRSN) is a late-stage clinical biotechnology company developing PrimeC, a disease-modifying treatment for neurodegenerative diseases, with completed Phase 2b trials in ALS and Alzheimer's disease.
Who is the CEO of NeuroSense Therapeutics Ltd.?
Mr. Alon Ben-Noon is the chief executive officer of NeuroSense Therapeutics Ltd. (NRSN).
Where is NeuroSense Therapeutics Ltd. headquartered?
NeuroSense Therapeutics Ltd. (NRSN) is headquartered in Herzliya, Israel.
What therapeutic areas does NeuroSense Therapeutics Ltd. focus on?
NeuroSense Therapeutics Ltd. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.